All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

When should we consider allo-SCT for patients with MDS?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to Corey Cutler, Dana-Farber Cancer Institute, Boston, US. We asked, when should we consider allogeneic stem cell transplantation for patients with MDS?

In this video, Cutler talks about the results from the Blood and Marrow Transplant Clinical Trials Network study 1102. Read a summary of the data presented here.

When should we consider allo-SCT for patients with MDS?

Share: